Lipid variability and risk of microvascular complications in Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: A post hoc analysis

Daniel Nyarko Hukportie, Fu-Rong Li, Rui Zhou, Jia-Zhen Zheng, Xiao-Xiang Wu, Meng-Chen Zou, Xian-Bo Wu

1Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China
2School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, China
3Department of General Surgery, 157th Hospital, General Hospital of Guangzhou Military Command, Guangzhou, China
4Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China

Correspondence
Xian-Bo Wu, Department of Epidemiology, School of Public Health, School of Public Health, Southern Medical University, Guangzhou, Guangdong, 510515, China; Email: wuxb1010@smu.edu.cn

Fu-Rong Li, School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, Guangdong, 518055, China. Email: lifr@sustech.edu.cn

Meng-Chen Zou, Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, 510000, China. Email: zoumc163@163.com

Abstract

Background: Greater lipid variability may cause adverse health events among diabetic patients. We aimed to examine the effect of lipid variability on the risk of diabetic microvascular outcomes among type 2 diabetes mellitus patients.

Methods: We assessed the association between visit-to-visit variability (measured by variability independent of mean) in high-density lipoprotein (HDL) cholesterol, low-density lipoprotein-cholesterol (LDL), triglyceride, and remnant cholesterol (RC) measurements among participants involved in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study and the risk of incident microvascular outcomes, including nephropathy, neuropathy, and retinopathy. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for potential confounders.

Results: There were 2400, 2470, and 2468 cases of nephropathy, neuropathy, and retinopathy during a follow-up period of 22,600, 21,542, and 26,701 person-years, respectively. Higher levels of HDL, triglyceride, and RC variability were associated with an increased risk of incident nephropathy and neuropathy. Compared with the lowest quartile, the fully adjusted HRs (95% CI) for the highest quartile of HDL, triglyceride, and RC variability for nephropathy risk were 1.57 (1.22, 2.01), 1.50 (1.18, 1.92), and 1.40 (1.09, 1.80), respectively; and for neuropathy, the corresponding risks were 1.36 (1.05, 1.75), 1.47 (1.14, 1.91), and 1.35 (1.04, 1.74), respectively. Null association was observed between LDL
Novo Nordisk; King Pharmaceuticals; Bayer HealthCare; Abbott Laboratories; Centers for Disease Control and Prevention; National Eye Institute; National Institute on Aging; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; National Heart, Lung, and Blood Institute

variability and all microvascular complications. Additionally, all associations of variability in the other lipids with retinopathy risk were null.

**Conclusion:** Among individuals with type 2 diabetes mellitus, HDL, triglyceride, and RC variability were associated with increased risks of nephropathy and neuropathy but not retinopathy. Trial registration: ClinicalTrials.gov., no. NCT00000620.

**KEYWORDS**
high-density lipoprotein, low-density lipoprotein, microvascular complications, remnant cholesterol, triglyceride

**Highlights**
Association of lipid variability with diabetic microvascular complications.

1 | **INTRODUCTION**

Dyslipidemia is a common presentation in individuals with type 2 diabetes mellitus (T2DM), even among those with good glycemic control. Indeed, individuals with T2DM have been found to have abnormally high levels of triglycerides, decreased high-density lipoproteins (HDL), and modest or normal levels of low-density lipoproteins (LDL). In a cross-sectional study of T2DM patients, the researchers found the prevalence of hypertriglyceridemia, abnormal HDL levels (<40 mg/dL), and abnormal levels of LDL (>130 mg/dL) to be 61.9%, 54.3%, and 8.9%, respectively, similar to the findings of other studies. These abnormal lipid levels have been implicated in the development of several diabetes-related complications including diabetic macrovascular and microvascular disease.

Meanwhile, higher variabilities in lipid variables have also been found to be detrimental to health among populations with or without diabetes. For example, in a study of approximately 1000 participants with clinical presentation of coronary disease involved in the Treating to New Target trial, greater variability in HDL, triglyceride, and LDL was found to be associated with cardiovascular events. Also, a recent study of over 10 000 T2DM patients showed that higher variability in HDL, LDL, and total cholesterol appeared to increase the risk of all-cause mortality whereas greater variability in HDL was associated with noncardiovascular deaths. However, few of these studies were on the relationship between lipid variability and diabetic microvascular complications. Diabetic microvascular complications, which comprise nephropathy, neuropathy, and retinopathy, together contribute hugely to the burden of diabetic-related morbidity and mortality. Reports show that during a lifetime, about 20%-40% of patients with T2DM would develop diabetic kidney disease, up to 50% would eventually develop diabetic neuropathy, and 10% are likely to develop diabetic retinopathy.

With the paucity of studies on the association between lipid variability and microvascular complication, we conducted a post hoc analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial to examine the relationship between intraindividual variability in HDL, LDL, triglyceride, and remnant cholesterol (RC) with diabetic microvascular complication. The ACCORD trial was a randomized, multicenter, double 2 × 2 factorial trial in 10 251 participants with T2DM. The current study gives a unique sample of participants with T2DM, with comprehensive baseline measurements and almost complete follow-up for diabetic microvascular complications, including nephropathy, neuropathy, and retinopathy.

2 | **METHODS**

2.1 | **Study design and subjects**

ACCORD was a randomized clinical trial of 10 251 participants with type 2 diabetes who were followed to assess the health effects of intensive glycemic, lipid, and blood pressure (BP) control as against standard control. The design and main results of the ACCORD study have been published previously. In brief, the ACCORD trial had three study arms: (1) glycemia trial (glycated hemoglobin [HbA1c] <6.0% vs 7.0% < HbA1c <7.9%), (2) lipid trial (fenofibrate vs placebo), and (3) BP trial (systolic BP <120 mm Hg vs systolic BP <140 mm Hg), with all participants involved in the glycemia trial. Recruitment of participants into the study began in January 2001 through to October 2005 from 77 clinical sites across
North America (ie, the United States and Canada). Participants in the ACCORD study were followed up until June 2009. Ethical approval for the ACCORD study was granted by institutional review boards of each clinical site and written informed consent was obtained from all recruited participants (trial registration: ClinicalTrials.gov., no. NCT00000620).

This current study was a post hoc analysis of data available for participants who did or did not participate in the lipid trial arm of the ACCORD study. In order to demonstrate the impact of lipid variability on microvascular complications in T2DM patients, participants with less than three lipid measurements \( (n = 554) \) were excluded. Then, for each microvascular outcome, individuals with the prevalent microvascular outcome at baseline and those who developed the outcome within the first year of the study were excluded from the analysis of the specific microvascular outcome; that is, for nephropathy outcome, the exclusion would be 1029 participants with prevalent macroalbuminuria, 33 with serum creatinine >3.3 mg/dL, and 2930 who developed incident nephropathy in the first year of the study (total exclusion = 3992); for neuropathy outcome, the exclusion would be 2566 participants with prevalent neuropathy and 1533 participants who developed incident neuropathy in the first year of the study (total exclusion = 4099); and for retinopathy, the exclusion would be 993 patients with retinopathy, 1191 patients with missing record on baseline retinopathy variable, and 778 patients who developed incident retinopathy within the first year of the study (total exclusion = 2962). The analytic samples for nephropathy, neuropathy, and retinopathy outcomes were 5705, 5598, and 6735, respectively (Figure 1).

### 2.2 Definition of lipid variability

During the ACCORD trial, a fasting plasma lipid profile was measured at baseline, then at 4 months, 8 months, 12 months, and yearly thereafter. We calculated remnant cholesterol as total cholesterol - LDL - HDL. Lipid variability was defined as the variation in HDL, LDL, triglyceride, and RC values between visits. Three indices of variability were used: (1) SD, (2) coefficient of variation (CV), and (3) variability independent of the mean (VIM). VIM was calculated as \( 100 \times \text{SD/mean}^2 \), where \( \beta \) is the regression coefficient, based on the natural logarithm of the SD on the natural logarithm of the mean. The uncorrected VIM was corrected using this formula: \( \text{VIM uncorrected} \times \text{mean of CV} \div \text{mean of VIM uncorrected} \).
Because SD and CV are correlated with the mean level, the corrected VIM (cVIM) was used as the primary variability measure in this study and CV and SD were used as a sensitivity analysis.

2.3 Study outcomes

The endpoints considered in our analysis were microvascular events defined as neuropathy (a composite of (1) new score of >2.0 on the Michigan Neuropathy Screening Instrument, (2) new loss of vibratory sensation [tested using 128 Hz tuning fork], (3) new loss of ankle jerk during Jendrassik maneuver, or (4) new loss of light touch [as measured by 10 g force monofilament test]); nephropathy (a composite of (1) development of macroalbuminuria, (2) development of renal failure, or (3) doubling of baseline serum creatinine or more than 20 mL/min/1.73 m² decrease in estimated glomerular filtration rate [eGFR]), and retinopathy (a composite of (1) retinal photocoagulation or vitrectomy to treat retinopathy, (2) eye surgery for cataract extraction, (3) three-line change in visual acuity [as measured using Log MAR visual acuity chart], or (4) severe vision loss [as measured by Snellen fraction <20/200]). Patients who experienced any one of the predefined microvascular events that comprised the composite neuropathy, nephropathy, and retinopathy outcome were considered to have experienced that specific disease. Table S1 shows the three predefined ACCORD microvascular end points and their frequency of assessment.

2.4 Statistical analysis

Participants’ characteristics were described using mean ± SD (SD) or median (25% and 75%) for continuous variables, depending on whether the data distribution was normal (assessed by the Shapiro-Wilk test); categorical variables were described by frequency and percentage. The association between HDL, LDL, triglyceride, and RC variability (as measured by cVIM) and the risk of outcomes was evaluated by using the quartiles of HDL, LDL, triglyceride, and RC variability.

Cox proportional hazards regression model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs), using HDL, LDL, triglyceride, and RC as a time-dependent covariate. Two models were used for each outcome. The basic model was adjusted for demographic factors and the full model was adjusted for demographic variables, lipid profile variables (mean values of HDL, LDL and triglyceride), and lipid medication use plus other covariates with p values <.05 in the univariate analysis (Table 1). Specifically, model 1 was adjusted for baseline age (continuous), sex (male or female), and race (white or non-white). Model 2 for nephropathy was adjusted for model 1 plus glycemia treatment arm (intensive or standard), BP vs lipid arm (standard BP, intensive BP, fibrate, and placebo), duration of diabetes, mean HbA1c, mean HDL, mean LDL, mean triglyceride, mean systolic BP, baseline eGFR, baseline body mass index (BMI), cardiovascular disease (CVD) history (yes or no), insulin use (yes or no), antihypertensives (yes or no), statin (yes or no), fibrate (yes or no), and other lipid medications (yes or no). For neuropathy, model 2 was adjusted for model 1 plus glycemia allocation, duration of diabetes, mean HDL, mean LDL, mean triglyceride, baseline BMI, cigarette smoking (yes or no), insulin, statin, fibrate, and other lipid medications. Model 2 for retinopathy was adjusted for model 1 plus glycemia allocation, BP vs lipid arm, duration of diabetes, mean values of HDL, LDL, triglyceride, and systolic BP, baseline BMI, insulin, statin, fibrate, and other lipid medications.

Other measures of variability, such as CV and SD, were used for sensitivity analyses; we also excluded participants who developed serious adverse events during the first 18 months of the study to test the robustness of the results. Furthermore, the effect of Hba1c and systolic BP variability on the study outcomes was examined by adjusting for Hba1c and systolic BP variability in all the full models. All statistical analyses were two sided, and we considered a p value of <.05 to be statistically significant. All analyses were performed using Stata (version 14.2; StataCorp, College Station, Texas).

3 RESULTS

Table 1 shows the distribution of participants’ characteristics according to whether they developed nephropathy, neuropathy, and retinopathy or not. Compared with participants who did not develop nephropathy, those who developed nephropathy were more likely to be men, belonged to the standard glycemia treatment arm, have a longer duration of diabetes, higher levels of BMI, HbA1c, SBP, triglyceride, RC, eGFR, but had lower levels of HDL, use antihypertensives, were less likely to have CVD, and were less likely to use fibrate and insulin. Participants who developed neuropathy were more likely to be older, of the white race, belonged to the standard glycemia treatment arm, had higher levels of triglyceride, RC, BMI, but had lower levels of HDL, and were less likely to use insulin. In addition, participants who developed retinopathy were more likely to be older, belonged to the white race, assigned to the standard treatment arm, had a longer
TABLE 1  Differences in baseline characteristics of participants with nephropathy, neuropathy, and retinopathy

| Characteristics                  | Nephropathy |   | Neuropathy |   | Retinopathy |   |
|----------------------------------|-------------|---|------------|---|-------------|---|
|                                  | No cases    |   | No cases   |   | No cases    |   |
|                                  | (n = 3305)  |   | (n = 3128) |   | (n = 4267)  |   |
| Age, y                           | 62.2 (57.6, 67.4) | .31 | 61.6 (57.4, 66.3) | <.001 | 60.9 (57, 65.6) | <.001 |
| Sex                              | <.001       |   | .051       |   | .062        |   |
| Male                             | 1994 (60.3) |   | 1856 (59.3) |   | 2708 (63.5) |   |
| White                            | 1549 (64.5) |   | 1632 (52.2) |   | 2715 (63.6) |   |
| Male                             | 1277 (53.2) | .003 | 1271 (51.5) | .006 | 1271 (51.5) | .020 |
| Race                             | .079        |   | <.001      |   | .023        |   |
| White                            | 1123 (46.8) |   | 1199 (48.5) |   | 1197 (48.5) |   |
| Age of trial                     | <.001       |   | .16        |   | .001        |   |
| Standard BP                      | 503 (21.0)  |   | 597 (24.2) |   | 618 (25.0)  |   |
| Intensive BP                     | 563 (23.5)  |   | 558 (22.6) |   | 576 (23.3)  |   |
| Lipid placebo                    | 766 (31.9)  |   | 670 (27.1) |   | 641 (26.0)  |   |
| Lipid fibrate                    | 568 (23.7)  |   | 645 (26.1) |   | 633 (25.6)  |   |
| Duration of diabetes, y          | 9 (5, 14)   | <.001 | 8 (5, 14) | .037 | 8 (5, 15)   | <.001 |
| HbA1c, %                         | 8 (7.5, 8.7) | .001 | 8.0 (7.5, 8.8) | .23 | 8 (7.5, 8.7) | .23 |
| TC, mg/dL                        | 178 (154.5, 206) | .47 | 179 (153, 208) | .57 | 177 (153, 206) | .63 |
| HDL, mg/dL                       | 41 (35, 49) | .001 | 41 (34, 47) | .011 | 40 (34, 48) | <.001 |
| LDL, mg/dL                       | 101 (82, 125) | .11 | 101 (82, 127) | .42 | 99 (80, 123) | .28 |
| Triglyceride, mg/dL              | 150 (104, 215.5) | <.001 | 150 (102, 224) | .032 | 161 (111, 238) | .017 |
| RC, mg/dL                        | 30 (21, 43) | <.001 | 30 (22, 45) | .30 | 32 (22, 47) | .017 |
| BMI, kg/m²                       | 133 (123, 144) | <.001 | 136 (125, 147) | .28 | 134 (124, 145) | .027 |
| eGFR, mL/min/1.73 m²             | 80.3 (68.8, 92.1) | <.001 | - | - | - | - |
| CVD history                      | .002        |   | .92        |   | .47         |   |
| Yes                              | 1031 (31.2) |   | 1017 (32.5) |   | 1433 (33.6) |   |
| Cigarette smoking                | .78         |   | .025       |   | .24         |   |
| Yes                              | 428 (13.0)  |   | 440 (14.1) |   | 640 (15.0)  |   |
| Insulin use                      | .004        |   | .018       |   | <.001       |   |
| Yes                              | 1081 (32.7) |   | 841 (26.9) |   | 832 (33.7)  |   |

(Continues)
duration of diabetes, higher levels of HDL, SBP, but lower levels of BMI, triglyceride, RC, eGFR, and were less likely to be on insulin. (Table 1). ACCORD recorded 2400, 2470, and 2468 cases of nephropathy, neuropathy, and retinopathy for a follow-up period of 22 600, 21 542, and 26 701 person-years, respectively (Table S2).

The rates of any nephropathy event generally increased with increasing quartiles of mean HDL, LDL, triglyceride, and RC as measured by cVIM (Figure S1). Also, the rates of neuropathy events generally increased with increasing quartiles of mean HDL, triglyceride, and RC (Figure S2) but for retinopathy outcome, an increase in rates was observed only for increasing quartiles of triglyceride and RC variability (Figure S3).

After controlling for potential confounding factors, higher levels of HDL, triglyceride, and RC variability measured by cVIM were associated with increased nephropathy risk. The HR and 95% CI for the highest quartile of HDL, triglyceride, and RC variability in the fully adjusted models were 1.57 (95% CI 1.22, 2.01), 1.50 (95% CI 1.16, 1.92), and 1.40 (95% CI 1.09, 1.80) for nephropathy, respectively compared with each lowest quartile (Table 2). However, the association of the highest quartile of LDL variability with incident nephropathy was not statistically significant (Table 2). When other variability measures were used as the supplementary analysis, higher variability in HDL, triglyceride, and RC measured by CV and SD was associated with an increased risk of nephropathy (Table S3). Also, the association of LDL variability as measured by CV and SD with incident nephropathy remained statistically insignificant (Table S3). The results also remained the same as the main analysis using cVIM after excluding participants who developed serious adverse effects in the first 18 months of the study (Table S4).

Similarly, higher variability in HDL, triglycerides, and RC was positively associated with an increased risk of neuropathy in the full models. Compared with the lowest quartile, the fully adjusted HRs (95% CIs) for the highest quartile of HDL, triglyceride, and RC variability were 1.36 (95% CI 1.05, 1.75), 1.47 (95% CI 1.14, 1.91), and 1.35 (95% CI 1.04, 1.74) for any neuropathy event (Table 3). However, the association between the highest quartiles of LDL variability and neuropathy was consistently null (Table 3).

A similar trend was also observed when CV was used in the supplementary analysis. CV of HDL, triglyceride, and RC was associated with an increased risk of neuropathy, but when SD was used, only the SD of triglyceride and RC was associated with an increased risk of neuropathy (Table S5). The results remained the same as the main analysis using cVIM after excluding participants who developed serious adverse effects in the first 18 months of the study (Table S6).
For retinopathy, higher variability in triglyceride and RC were significantly associated with an increased risk of retinopathy in the basic model (adjusted for age, sex, and race). However, these statistically significant associations were lost in the fully adjusted models (Table 4). A similar trend was confirmed in the sensitivity analysis when CV or SD was used as the variability measure (Table S7). Results remained materially the same after excluding participants with any serious adverse event that occurred in the first 18 months of follow-up (Table S8).

Also, the results remained materially the same for all the study outcomes after further adjusting for variability in HbA1c and systolic BP in the full models (Table S9).

4 | DISCUSSION

In this post hoc study of individuals with T2DM who took part in the ACCORD trial, we found higher levels of HDL, triglyceride, and RC variability to be associated with an increased risk of nephropathy and neuropathy, whereas a nonsignificant association was observed between all lipid variability measures and retinopathy after adjusting for potential confounding factors. This study provides epidemiologic evidence regarding the associations between visit-to-visit variabilities in lipid measures and the risk of diabetic nephropathy and neuropathy, which can be useful in delineating microvascular risk in individuals with T2DM.

Greater visit-to-visit fluctuation in lipid profiles has been reported to negatively affect renal function in individuals with or without T2DM. In a study of 457 individuals with T2DM who were followed up for about 6.8 years, the researchers found triglyceride variability (defined by SD) to be significantly associated with incident microalbuminuria. Also, Chang et al found HDL variability to be associated with an increased risk of nephropathy progression in a sample of 864 T2DM patients who were followed up for a mean of 3.8 years.

### Table 2

| Variables and categories | Events | Incidence rate/100 person-year | HR [95% CI] | p value | HR [95% CI] | p value |
|--------------------------|--------|-------------------------------|-------------|---------|-------------|---------|
| **HDL cholesterol**      |        |                               |             |         |             |         |
| Q1                       | 534    | 9.5                           | REF.        |         | REF.        |         |
| Q2                       | 604    | 10.6                          | 1.17 [1.02, 1.35] | .022   | 1.22 [1.06, 1.40] | .005 |
| Q3                       | 598    | 10.5                          | 1.21 [1.00, 1.46] | .046   | 1.26 [1.04, 1.53] | .016 |
| Q4                       | 664    | 11.9                          | 1.44 [1.13, 1.85] | .004   | 1.57 [1.22, 2.01] | <.001 |
| **LDL cholesterol**      |        |                               |             |         |             |         |
| Q1                       | 537    | 9.6                           | REF.        |         | REF.        |         |
| Q2                       | 613    | 11.1                          | 1.17 [1.02, 1.34] | .027   | 1.13 [0.98, 1.29] | .092 |
| Q3                       | 638    | 11.1                          | 1.19 [0.99, 1.44] | .065   | 1.19 [0.98, 1.43] | .077 |
| Q4                       | 612    | 10.6                          | 1.16 [0.90, 1.50] | .247   | 1.17 [0.91, 1.52] | .216 |
| **Triglyceride**         |        |                               |             |         |             |         |
| Q1                       | 553    | 9.9                           | REF.        |         | REF.        |         |
| Q2                       | 591    | 10.3                          | 1.14 [1.00, 1.31] | .058   | 1.12 [0.97, 1.29] | .116 |
| Q3                       | 633    | 11.1                          | 1.37 [1.13, 1.65] | .001   | 1.32 [1.09, 1.60] | .004 |
| Q4                       | 623    | 11.1                          | 1.52 [1.19, 1.95] | .001   | 1.50 [1.16, 1.92] | .002 |
| **Remnant cholesterol**  |        |                               |             |         |             |         |
| Q1                       | 556    | 10.0                          | REF.        |         | REF.        |         |
| Q2                       | 577    | 10.0                          | 1.07 [0.93, 1.23] | .325   | 1.08 [0.94, 1.24] | .278 |
| Q3                       | 649    | 11.4                          | 1.34 [1.11, 1.62] | .002   | 1.32 [1.09, 1.59] | .005 |
| Q4                       | 618    | 11.0                          | 1.41 [1.09, 1.81] | .008   | 1.40 [1.09, 1.80] | .009 |

Note: Model 1: Adjusted for age, sex and race.
Note: Model 2: Adjusted for age, sex, race, allocation to glycemia treatment arm, BP vs lipid treatment arm, duration of diabetes, mean HbA1c, mean LDL, mean HDL, mean triglyceride, mean systolic BP, baseline eGFR, baseline BMI, cardiovascular disease history, antihypertensive use, insulin, statin, fibrate, and other lipid medication.

Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence interval; cVIM, corrected variability independent of mean; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein.
similar to the findings assessing the association of lipid variability with a decrease in GFR among over 7000 diabetic patients. However, these studies were on a relatively small sample size or limited by lack of a centralized laboratory assessment. Using data from a large sample of participants with T2DM (n = 6735) in a randomized, multicenter, double 2 × 2 factorial trial, we confirmed that HDL and triglyceride variability may be associated with renal function decline. Our study also found higher variability of RC to be associated with nephropathy risk. Studies on RC variability and risk of nephropathy are limited. A study of patients with type 1 diabetes mellitus (T1DM) did not find an association between RC variability and progression of renal function decline in their full model, although a statistically significant relationship was found between RC concentration and nephropathy progression. Differences in lipid profiles between T1DM and T2DM may account for the conflicting results of RC variability and nephropathy in our study and others. For instance, whereas patients with T2DM may have decreased HDL, T1DM patients are more likely to have normal or even high levels of HDL unless under inadequate glycemic control.

Contrary to the results of some studies reporting a positive link between LDL variability and renal function decline among individuals with T2DM, our study did not find LDL variability to be associated with incident nephropathy. The reason for this unexpected null association is unknown, but we could speculate that because some participants received lipid treatment with the aim of maintaining good control of LDL levels, the potentially harmful effect of high variability in LDL may have been mitigated. Of note is that a study using a large sample of Korean participants with T2DM (n = 13 800) and nondiabetic controls (n = 185 898) observed a nonsignificant association between higher variability of LDL (measured by average real variability) and CVD. Similarly, in a recent 5-year follow-up study of 4475 nondiabetic Chinese participants, the researchers found a nonsignificant association between LDL variability and incident T2DM. Further studies may be necessary to clarify the discordant results of the relationship of LDL variability with renal function decline.

### Table 3: Quartiles of lipid variability (cVIM) measures and risk of neuropathy

| Variables and categories | Events | Incidence rate/100 person-year | HR [95% CI] | p value | HR [95% CI] | p value |
|--------------------------|--------|-------------------------------|-------------|---------|-------------|---------|
| HDL cholesterol          |        |                               |             |         |             |         |
| Q1                       | 572    | 10.8                          | REF.        |         | REF.        |         |
| Q2                       | 625    | 11.6                          | 1.16 [1.01, 1.32] | .036    | 1.18 [1.03, 1.36] | .017    |
| Q3                       | 634    | 11.7                          | 1.23 [1.02, 1.49] | .030    | 1.26 [1.04, 1.52] | .018    |
| Q4                       | 639    | 11.7                          | 1.32 [1.02, 1.70] | .032    | 1.36 [1.05, 1.75] | .020    |
| LDL cholesterol          |        |                               |             |         |             |         |
| Q1                       | 590    | 11.1                          | REF.        |         | REF.        |         |
| Q2                       | 632    | 11.9                          | 1.14 [1.00, 1.31] | .053    | 1.13 [0.99, 1.30] | .079    |
| Q3                       | 632    | 11.6                          | 1.19 [0.99, 1.44] | .069    | 1.16 [0.96, 1.41] | .122    |
| Q4                       | 616    | 11.2                          | 1.22 [0.94, 1.57] | .132    | 1.16 [0.90, 1.51] | .253    |
| Triglyceride             |        |                               |             |         |             |         |
| Q1                       | 559    | 10.3                          | REF.        |         | REF.        |         |
| Q2                       | 649    | 12.4                          | 1.33 [1.16, 1.53] | <.001   | 1.34 [1.16, 1.53] | <.001   |
| Q3                       | 638    | 11.7                          | 1.34 [1.11, 1.63] | .003    | 1.36 [1.12, 1.65] | .002    |
| Q4                       | 624    | 11.5                          | 1.46 [1.13, 1.89] | .004    | 1.47 [1.14, 1.91] | .003    |
| Remnant cholesterol      |        |                               |             |         |             |         |
| Q1                       | 551    | 10.2                          | REF.        |         | REF.        |         |
| Q2                       | 663    | 12.7                          | 1.32 [1.15, 1.51] | <.001   | 1.31 [1.14, 1.50] | <.001   |
| Q3                       | 620    | 11.3                          | 1.21 [1.00, 1.47] | .050    | 1.23 [1.01, 1.49] | .039    |
| Q4                       | 636    | 11.7                          | 1.33 [1.02, 1.72] | .032    | 1.35 [1.04, 1.74] | .024    |

**Note:** Model 1: Adjusted for age, sex and race. Model 2: Adjusted for age, sex, race, allocation to glycemia treatment arm, duration of diabetes, mean LDL, mean HDL, mean triglyceride, baseline BMI, cigarette smoking, insulin, statin, fibrate, and other lipid medications.

**Abbreviations:** BMI, body mass index; CI, confidence interval; cVIM, corrected variability independent of mean; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein.
with adverse health outcomes, including renal function decline. Overall, our study adds to the evidence that high HDL, triglyceride, and RC variability may be associated with an increased risk of nephropathy.

The exact mechanism underlining the pathological link between increased variability in HDL, triglyceride, and RC and some specific microvascular is not clear. However, it has been suggested that abnormal lipid levels may directly affect renal function by triggering harmful renal lipid disturbance and indirectly through a general inflammatory process or oxidative stress, vascular injuries, and alterations in signaling molecules for normal renal function. For example, hypertriglyceridemia, which is a key manifestation of dyslipidemia among patients with T2DM, has been shown to trigger the secretion of inflammatory mediators and have a proapoptotic effect on the endothelium of the kidney in vitro and vivo.

Our results showed a significant association between greater HDL, triglyceride, and RC variability and neuropathy risk, whereas LDL variability did not. There seems to be a lack of data on the relationship between lipid profile variability and peripheral neuropathy; however, some studies have found a significant association between glycemic variability and neuropathy. That notwithstanding, dyslipidemia has been identified to be a risk factor for peripheral and autonomic neuropathy. In a 13-year follow-up longitudinal study of 1533 diabetic patients, the authors found lower levels of HDL and LDL to be significantly associated with a higher risk of polyneuropathy. Because abnormal levels of lipid profile may be indicative of instability in lipid control (dyslipidemia), a similar deleterious effect may be influenced by increased lipid variability on sensory cells in individuals with diabetes. Although the pathophysiological mechanism underlying the link between dyslipidemia and neuropathy is not yet clear, studies on animal models suggest that impaired lipid metabolism in the presence of dyslipidemia may impair normal mitochondrial processes in dorsal root ganglia and affect mitochondrial size of neurons. Furthermore, denmyelination as a result of

---

**Table 4**  Quatiles of lipid variability (cVIM) measures and risk of retinopathy

| Variables & categories | Events | Incidence rate/100 person-year | HR [95% CI] | p value | HR [95% CI] | p value |
|------------------------|--------|--------------------------------|-------------|--------|-------------|--------|
| HDL cholesterol        |        |                                |             |        |             |        |
| Q1                     | 667    | 9.1                           | REF.        |        | REF.        |        |
| Q2                     | 697    | 9.3                           | 1.09 [0.95, 1.25] | .207 | 1.11 [0.97, 1.27] | .129 |
| Q3                     | 713    | 9.4                           | 1.12 [0.93, 1.35] | .237 | 1.14 [0.95, 1.38] | .171 |
| Q4                     | 736    | 9.7                           | 1.22 [0.96, 1.56] | .110 | 1.23 [0.96, 1.58] | .099 |
| LDL cholesterol        |        |                                |             |        |             |        |
| Q1                     | 677    | 9.1                           | REF.        |        | REF.        |        |
| Q2                     | 710    | 9.6                           | 1.04 [0.91, 1.19] | .546 | 1.05 [0.92, 1.21] | .450 |
| Q3                     | 695    | 9.0                           | 1.00 [0.83, 1.20] | .981 | 1.02 [0.85, 1.23] | .833 |
| Q4                     | 731    | 9.5                           | 1.00 [0.78, 1.28] | .978 | 1.02 [0.79, 1.30] | .887 |
| Triglyceride           |        |                                |             |        |             |        |
| Q1                     | 659    | 8.9                           | REF.        |        | REF.        |        |
| Q2                     | 707    | 9.4                           | 1.07 [0.94, 1.23] | .300 | 1.07 [0.93, 1.22] | .356 |
| Q3                     | 745    | 9.9                           | 1.18 [0.98, 1.42] | .076 | 1.16 [0.96, 1.40] | .113 |
| Q4                     | 702    | 9.2                           | 1.18 [0.92, 1.51] | .203 | 1.18 [0.92, 1.52] | .199 |
| Remnant cholesterol    |        |                                |             |        |             |        |
| Q1                     | 650    | 8.8                           | REF.        |        | REF.        |        |
| Q2                     | 706    | 9.4                           | 1.07 [0.93, 1.22] | .348 | 1.07 [0.93, 1.23] | .323 |
| Q3                     | 745    | 9.8                           | 1.22 [1.01, 1.47] | .037 | 1.20 [0.99, 1.44] | .059 |
| Q4                     | 712    | 9.4                           | 1.20 [0.93, 1.54] | .158 | 1.21 [0.94, 1.56] | .137 |

*Note: Model 1: Adjusted for age, sex, and race.*
*Note: Model 2: Adjusted for age, sex, race, allocation to glycemia treatment arm, BP vs lipid treatment arm, duration of diabetes, mean LDL, mean HDL, mean triglyceride, mean systolic BP, baseline BMI, insulin, statin, fibrate and other lipid medications.*

*Abbreviations: BMI, body mass index; CI, confidence interval; cVIM, corrected variability independent of mean; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein.*
dyslipidemia has also been suggested as another plausible mechanism for lipid-induced injury of neurons, which may contribute to the development of neuropathy.46

Meanwhile, our analysis for the relationship between all variability measures of lipid profile with retinopathy was null. Not many studies have explored the relationship between lipid variability and retinopathy among individuals with T2DM to corroborate our results. However, our results agree with one study that also found variability of RC not to be related to retinopathy among 5150 T1DM patients.19 The reason for the null association between all lipid profile variability and retinopathy is not clear, but it could be due to the duration required for lipid variability to cause recognizable pathological changes in the eye. On the whole, the incidence of retinopathy was lower at the close of the study compared to the incidence of nephropathy and neuropathy, suggesting that the rate of developing retinopathy was slower among our study population. Hence, potential risk factors such as dyslipidemia and for that matter, lipid variability linked to the pathogenesis of nephropathy and neuropathy may probably take a longer duration to cause recognizable pathological changes in the retina. Further epidemiological studies may be required to verify these results.

The strength of our study includes the use of a relatively large number of subjects from the ACCORD trial, which had a formalized follow-up lipid measurement schedule. The use of three variability measures adds to the robustness of the study. There was also a special examination of microvascular complications at baseline and subsequent visits, which permitted the accurate assessment of the effect of lipid variability on microvascular complication risk. However, some limitations also need to be considered: (1) the lipid treatment patients received during the trial may affect lipid variability—however, to address this limitation, we additionally adjusted for various lipid treatments in our full model; (2) because participants in the ACCORD study may have more advanced diabetes with associated comorbidities, an extension of findings to healthier and younger T2DM patients should be done cautiously; and (3) the observational nature of this study can only imply an association but not causation, other residual or unrecorded confounding factors may have contributed to the observed results.

In conclusion, long-term greater variability in HDL, triglyceride, and RC were associated with the risk of incident nephropathy and neuropathy but not retinopathy among individuals with T2DM. Healthcare providers may target lower variability in lipid (HDL, triglyceride, and RC) in patients with T2DM in order to reduce the risk of microvascular complications.

**AUTHOR CONTRIBUTION**
Daniel Nyarko Hukportie and Fu-Rong Li conceived the study, analyzed the data, and wrote the manuscript. Rui Zhou, Jia-Zhen Zheng, Xiao-Xiang Wu, Meng-Chen Zou, Xand Ian-Bo Wu contributed to the discussion and reviewed/edited the manuscript. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGEMENTS**
The ACCORD study was supported by grants (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01- HC-95183, N01-HC-95184, IAA-Y1-HC-9035, and IAA-Y1-HC-1010) from the National Heart, Lung, and Blood Institute; by other components of the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Eye Institute; by the Centers for Disease Control and Prevention; and by General Clinical Research Centers. The following companies provided study medications, equipment, or supplies: Abbott Laboratories, Amylin Pharmaceutical, AstraZeneca Pharmaceuticals LP, Bayer HealthCare LLC, Closer Healthcare Inc., GlaxoSmithKline Pharmaceuticals, King Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals, Inc., Novo Nordisk, Inc., Omron Healthcare, Inc., Sanofi-Aventis U.S., and Takeda Pharmaceuticals Inc.

**FUNDING INFORMATION**
This study was supported by the National Natural Science Foundation of China (82173607), the Guangdong Basic and Applied Basic Research Foundation (2021A15 1501684), Open Project of the Guangdong Provincial Key Laboratory of Tropical Disease Research (2020B121 2060042) and Guangzhou Science and Technology Project (202102080597). Funders had no role in the design of the study, the analysis and interpretation of data, and the writing of the paper.

**CONFLICT OF INTEREST**
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**
The study was reviewed and approved by ACCORD Protocol Review Committee appointed by National Heart, Lung, and Blood Institute (NHLBI) and local institutional review boards of participating clinical sites. The patients/participants provided their written informed consent to participate in this study.
DATA AVAILABILITY STATEMENT
The data sets generated and/or analyzed during the current study are available in the Biologic Specimen and Data Repository, https://biolincc.nhlbi.nih.gov/studies/accord/

ORCID
Xian-Bo Wu https://orcid.org/0000-0002-2706-9599

REFERENCES
1. Feingold KR. Dyslipidemia in Diabetes. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. MDText.com, Inc; 2000.
2. Shahwan MJ, Jairoun AA, Farajallah A, Shanabl S. Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes. Diabetes Metab Syndr Clin Res Rev. 2019;13(4):2387-2392.
3. Das H, Banik S. Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: a cross-sectional study. Diabetes Metab Syndr. 2019;13(1):252-257.
4. Bhuiyan AS, Bari MA, Aditya G, et al. Prevalence and pattern of dyslipidemia in diabetes mellitus patients admitted in the Department of Cardiology, Mymensingh medical college hospital, Mymensingh, Bangladesh. Mymensingh Med J. 2021;30(1):21-27.
5. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 2020;19(1):42.
6. Yin L, Zhang D, Ren Q, Su X, Sun Z. Prevalence and risk factors of diabetic retinopathy in diabetic patients: a community based cross-sectional study. Medicine. 2020;99(9):e19236.
7. Sacks FM, Herrmans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129(9):999-1008.
8. Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ. The impact of serum lipids on risk for micro-angiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012;11(1):109.
9. Bardini G, Innocenti M, Rotella CM, Giannini S, Mannucci E. Variability of triglyceride levels and incidence of microalbuminuria in type 2 diabetes. J Clin Lipid. 2016;10(1):109-115.
10. Lee S, Zhou J, Wong WT, et al. Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. BMC Endocr Disord. 2021;21(1):94.
11. Waters DD, Bangalore S, Fayyad R, et al. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. J Clin Lipid. 2018;12(2):356-366.
12. Lee EY, Yang Y, Kim HS, et al. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention. Atherosclerosis. 2018;279:1-9.
13. Takenouchi A, Tsuboi A, Kitaoka K, et al. Visit-to-visit low-density lipoprotein cholesterol variability is an independent determinant of carotid intima-media thickness in patients with type 2 diabetes. J Clin Med Res. 2017;9(4):310-316.
14. Wan EYF, Yu EYT, Chin WY, et al. Greater variability in lipid measurements associated with kidney diseases in patients with type 2 diabetes mellitus in a 10-year diabetes cohort study. Sci Rep. 2021;11(1):8047.
15. Jansson Sigfrids F, Dahlström EH, Forsblom C, et al. Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes. J Intern Med. 2021;290(3):632-645.
16. Chang YH, Chang DM, Lin KC, Hsieh CH, Lee YJ. High-density lipoprotein cholesterol and the risk of nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2013;23(8):751-757.
17. Wang MC, Li CI, Liu CS, et al. Effect of blood lipid variability on mortality in patients with type 2 diabetes: a large single-center cohort study. Cardiovasc Diabetol. 2021;20(1):228.
18. Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamsheh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational Achieve study. Diabetol Metab Syndr. 2013;5(1):57.
19. Cheema S, Maisonneuve P, Zirie M, et al. Risk factors for microvascular complications of diabetes in a high-risk Middle East population. J Diabetes Res. 2018;2018:8964027.
20. Association AD. 11. Microvascular complications and foot care: <em>standards of medical care in Diabetes</em>–2020. Diabetes Care. 2020;43(Suppl 1):S135-S151.
21. Zhou R, Li F, Chen G, Fu Q, Gu S, Wu X. Associations between general and abdominal obesity and incident diabetic neuropathy in participants with type 2 diabetes mellitus. J Diabetes. 2021;13(13):33-42.
22. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay eye study. Ophthalmology. 2008;115(11):1869-1875.
23. Hukportie DN, Li FR, Zhou R, Zou MC, Wu XX, Wu XB. Association of Predicted Lean Body Mass and fat Mass with Incident Diabetic Nephropathy in participants with type 2 diabetes mellitus: a post hoc analysis of ACCORD trial. Front Endocrinol. 2021;12:719666.
24. ACCORD. ACCORDION: The ACCORD Follow-On Study Protocol (March 18, 2011–Version G). 2011. https://biolincc.nhlbi.nih.gov/media/studies/accord/ACCORDION_Protocol.pdf?link_time=2019-06-27_12:36:32.59776.
25. Buse JB, Bigger JT, Byington RP, et al. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i-33i.
26. Papademetriou V, Zaheer M, Doumas M, et al. Cardiovascular outcomes in action to control cardiovascular risk in diabetes: impact of blood pressure level and presence of kidney disease. Am J Nephrol. 2016;43(4):271-280.
27. Elam MB, Ginsberg HN, Lovato LC, et al. Association of Fenofibrate Therapy with Long-term Cardiovascular Risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2(4):370-380.
28. Hukportie DN, Li F-R, Zhou R, Zheng J-Z, Wu X-X, Wu X-B. Anthropometric measures and incident diabetic nephropathy in participants with type 2 diabetes mellitus. Front Endocrinol. 2021;12:706845.
29. Koh ES, Kim M, Kim MK, et al. Intra-individual variability in high density lipoprotein cholesterol and risk of end-stage renal
disease: a nationwide population-based study. *Atherosclerosis*. 2019;286:135-141.

30. Ceriello A, De Cosmo S, Rossi MC, et al. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. *Diabetes Obes Metab*. 2017;19(11):1570-1578.

31. Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes Dyslipidemia. *Diabetes Ther*. 2016;7(2):203-219.

32. Youk TM, Kang MJ, Song SO, Park E-C. Effects of BMI and LDL-cholesterol change pattern on cardiovascular disease in normal adults and diabetics. *BMJ Open Diabetes Res Care*. 2020;8(2):e001340.

33. Sun Q, Liu J, Wu L, et al. Associations of visit-to-visit variabilities and trajectories of serum lipids with the future probability of type 2 diabetes mellitus. *Lipids Health Dis*. 2021;20(1):168.

34. Bobulescu IA. Renal lipid metabolism and lipotoxicity. *Curr Opin Nephrol Hypertens*. 2010;19(4):393-402.

35. Ng KF, Aung HH, Rutledge JC. Role of triglyceride-rich lipoproteins in renal injury. *Contrib Nephrol*. 2011;170:165-171.

36. Hu Y-m, Zhao L-h, Zhang X-l, et al. Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients. *Endocrine*. 2018;60(2):292-300.

37. Xu F, Zhao L-H, Su J-B, et al. The relationship between glycaemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. *Diabetol Metab Syndr*. 2014;6(1):139.

38. Song L, Zhou L, Tang Z. An association analysis of lipid profile and diabetic cardiovascular autonomic neuropathy in a Chinese sample. *Lipids Health Dis*. 2016;15(1):122.

39. Khawaja N, Abu-Shennar J, Saleh M, Dahbour SS, Khader YS, Aljouni KM. The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan. *Diabetol Metab Syndr*. 2018;10:8.

40. Aleidan FAS, Ahmad BA, Alotaibi FA, et al. Prevalence and risk factors for diabetic peripheral neuropathy among Saudi hospitalized diabetic patients: a nested case-control study. *Int J Gen Med*. 2020;13:881-889.

41. Al-Ani FS, Al-Nimer MS, Ali FS. Dyslipidemia as a contributory factor in etiopathogenesis of diabetic neuropathy. *Indian J Endocrinol Metab*. 2011;15(2):110-114.

42. Andersen ST, Witte DR, Dalsgaard E-M, et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark. *Diabetes Care*. 2018;41(5):1068-1075.

43. Rumora AE, Lentz SI, Hinder LM, et al. Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons. *FASEB J*. 2018;32(1):195-207.

44. Savelieff MG, Callaghan BC, Feldman EL. The emerging role of dyslipidemia in diabetic microvascular complications. *Curr Opin Endocrinol Diabetes Obes*. 2020;27(2):115-123.

45. Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. *Diabetes*. 2009;58(10):2376-2385.

46. Cai Z, Yang Y, Zhang J. A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy. *Sci Rep*. 2021;11(1):499.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Hukportie DN, Li F-R, Zhou R, et al. Lipid variability and risk of microvascular complications in Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: A post hoc analysis. *Journal of Diabetes*. 2022;14(6):365-376. doi:10.1111/1753-0407.13273